Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab (Q35050082)

6 August 2017

title

Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab (English)

1 reference

6 August 2017

main subject

diabetic macular edema

1 reference

R Channa

1

1 reference

6 August 2017

R Sophie

2

1 reference

6 August 2017

A A Khwaja

3

1 reference

6 August 2017

D V Do

4

1 reference

6 August 2017

G Hafiz

5

1 reference

6 August 2017

Q D Nguyen

6

1 reference

6 August 2017

P A Campochiaro

7

1 reference

6 August 2017

READ-2 Study Group

8

1 reference

6 August 2017

publication date

22 November 2013

1 reference

6 August 2017

1 reference

6 August 2017

volume

28

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

269-278

1 reference

Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3965803

Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FEYE.2013.245

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24263379

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/EYE.2013.245

1 reference

6 August 2017

1 reference

6 August 2017

1 reference